VAMP2 can interact with other GPCRs, such as the beta-2 adrenergic receptor and the mu-opioid receptor (MOR this technology, they evidenced the presence of VAMP2, specifically in recycling vesicles containing MOR These data are fascinating because in the case of MOR, which is a receptor with several splicing variants modulated by different opioids, either endogenous or exogenous, promoving a differential organization of MOR Since MOR receptor regulates pain perception and reward, the dysfunction in the MOR-SNARE complex interaction

EOPs): β-endorphin, enkephalins and dynorphins, and four opioid receptors (ORs): μ-opioid receptor (MOR several reports that have addressed the differences in the mechanisms of transduction triggered by MOR Therefore to understand better the functions of arrestins in MOR signaling, Shiraki et al., explored the function of β-arrestin 2 in MOR signaling using the SH-SY5Y cell line that endogenously expresses MOR and was modified through CRISPR/Cas9 to knock out β-arrestin 1 and 2 gene expression.

June 2022 "Ottawa, Canada, May 10, 2022 — Orion Biotechnology Canada Ltd, a drug discovery and development Oliver Hartley , Orion’s Vice-President Drug Discovery, will present Orion’s novel technology for targeting His presentations will describe Orion’s drug discovery platform, one of the fastest drug discovery solutions Hartley will also present new data on Orion’s CCR2 antagonist, OB-004, demonstrating the ability of this

Morphine, the most widely used analgesic, relieves severe pain by activating the μ-opioid receptor (MOR The mechanism by which the MOR distinguishes between the two is unclear. , and I322A also significantly attenuated the potency of MOR on EM-1, confirming that binding deep in the pocket is critical for the agonistic effect of MOR. basis for the discovery of new ligands for MOR at the atomic level."

December 2021 "Ottawa, Ontario, Canada, Nov. 30, 2021 -- Orion Biotechnology , a clinical stage company

July 2022 " Orion Biotechnology and Peptilogics are pursuing AI-driven drug discovery to explore new

The primary analgesic target of opioids is the μ-opioid receptor (MOR). Here we investigated a potential mechanism for regulation of PLC signaling downstream of MOR in HEK293 cells and found that MOR alone could not stimulate PLC, but rather required a coincident signal from regulators, Gβγ or Gq, ex vivo in periaqueductal gray (PAG) slices increased the potency of the selective MOR Ultimately this could lead to identification of new non-MOR targets that would allow for lower dose utilization

For example, μ opioid receptor (MOR) interacts with Gαi/o and Gαz subunits, which have a slow enzymatic accelerate GTP hydrolysis reducing the activity of the Gα subunit and resulting in negative regulation of MOR

To solve this industry-wide problem, Orion Biotechnology (Orion) is introducing a novel solution driven Orion’s PROcisionXᵀᴹ Platform In Orion’s discovery process, shape space at the TM domain ‘message’ site Figure 2: Workflow in Orion’s PROcisionXᵀᴹ platform. Figure 4: Payload delivery using Orion’s superagonist analogs on target cells expressing CCR5. About Orion Biotechnology Orion’s mission is to unlock the therapeutic potential of previously undruggable

Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients Orion Webinars February 20, 2024 | Career Opportunities in Pharmacology and Drug Discovery March 13 - 15 | 9th German

Participate in Upcoming Investor and Industry Conferences Sosei and IPJ to become Nxera Pharma from April Orion Opportunities in Pharmacology and Drug Discovery NEW March 13 - 15 | Biologics 2024 March 13 - 15 | 9th German

article on Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling Alberto Gonzalez-Hernandez, Hermany

Approaches to GPCR Drug Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German

development GPCR Events, Meetings, and Webinars March 13 - 15 | Biologics 2024 March 13 - 15 | 9th German

Development The pathway of opioid drugs into cellular structures Inversago Pharma will present at BBHIC 2023 Orion

, and more Illuminating the druggable genome: Pathways to progress Industry News Anatole Klepatsky, Orion's

GPCR Research GPCR Events, Meetings, and Webinars March 13 - 15 | Biologics 2024 March 13 - 15 | 9th German

Orion Biotechnology Completes Discovery of First-in-Class Molecule Against Undrugged GPCR Target in Four

MI was introduced to rats by permanent left anterior descending coronary artery (LAD) ligation.

Webinars February 20, 2024 | Career Opportunities in Pharmacology and Drug Discovery March 13 - 15 | 9th German

Industry News Orion Biotechnology at the AACR 2023.

NEW February 20, 2024 | Career Opportunities in Pharmacology and Drug Discovery March 13 - 15 | 9th German

Conference and Exhibition February 11 - 14, 2024 | 2024 BPS Annual Meeting NEW March 13 - 15 | 9th German

chemokine receptor 3 Industry News New cannabinoid CB1 receptor antagonists disclosed in Inversago patent Orion

Machine Learning Model Three GPCR Companies Earn Prestigious Best Places to Work Certification in 2023 Orion

Inês Pinheiro and Oliver Hartley from the Orion Biotechnology team on their recent study on Arylsulfatases

Meeting February 20, 2024 | Career Opportunities in Pharmacology and Drug Discovery March 13 - 15 | 9th German

Industry News Orion Biotechnology will be participating in a panel discussion at the LSX World Congress